Get the Stockscreener App
9.22
2.88%
-0.32
After Hours:
9.22
Organon Co stock is traded at $9.22, with a volume of 3.68M.
It is down -2.88% in the last 24 hours and down -28.34% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$9.54
Open:
$9.4
24h Volume:
3.68M
Relative Volume:
0.67
Market Cap:
$2.40B
Revenue:
$6.29B
Net Income/Loss:
$750.00M
P/E Ratio:
3.2014
EPS:
2.88
Net Cash Flow:
$586.00M
1W Performance:
+6.62%
1M Performance:
-28.34%
6M Performance:
-41.62%
1Y Performance:
-55.75%
1-Day Range:
$9.17
$9.45
1-Week Range:
$8.76
$9.615
52-Week Range:
$8.01
$23.10
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
9.22 | 2.26B | 6.29B | 750.00M | 586.00M | 2.88 |
|
LLY
Lilly Eli Co
|
738.06 | 642.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.93 | 367.19B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.08 | 322.44B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.76 | 222.20B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.50 | 302.90B | 43.59B | 15.04B | 10.74B | 3.3766 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Levi & Korsinsky Urges Organon & Co. (OGN) Shareholders to Act Before Lead Plaintiff Deadline July 22, 2025 - ACCESS Newswire
Class Action Filed Against Organon & Co. (OGN)July 22, 2025 Deadline to Join – Contact Levi & Korsinsky - GlobeNewswire
Law Offices of Howard G. Smith Encourages Organon & Co. (OGN) Investors To Inquire About Securities Fraud Class Action - Business Wire
Did You Lose Money on Organon & Co. (OGN)? Levi & Korsinsky Urges Investors to Act Before July 22, 2025 - ACCESS Newswire
Shareholders who lost money on Organon & Co. (NYSE: OGN). Should Contact Wolf Haldenstein - GlobeNewswire
Shareholders who lost money on Organon & Co. (NYSE: OGN). Should Contact Wolf Haldenstein - GlobeNewswire Inc.
Shareholders that lost money on Organon & Co.(OGN) should contact Levi & Korsinsky about pending Class ActionOGN - PR Newswire
Why Organon & Co. (OGN) Surged On Thursday - Insider Monkey
Nuveen Asset Management LLC Reduces Stake in Organon & Co. (NYSE:OGN) - Defense World
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Organon & Co. - GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN - TradingView
Investors who lost money with shares of Organon & Co. (NYSE: OGN) - openPR.com
Levi & Korsinsky Notifies Organon & Co. (OGN) Shareholders of Class Action Lawsuit and July 22, 2025 Deadline - ACCESS Newswire
Shareholders of Organon & Co. Should Contact The Gross Law - GlobeNewswire
Shareholders of Organon & Co. Should Contact The Gross Law Firm Before July 22, 2025 to ... - Bluefield Daily Telegraph
Shareholders of Organon & Co. Should Contact The Gross Law Firm Before July 22, 2025 to Discuss Your Rights – OGN - TradingView
Organon & Co. (OGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Organon & Co (OGN) Stock Climbs Over 4%: A Value Signal with a Dividend Kicker? - Daily Chhattisgarh News
OGN REMINDER: Organon & Co. Investors with Losses are - GlobeNewswire
OGN REMINDER: Organon & Co. Investors with Losses are Notified of the Pending Securities Fraud Class Action – Contact BFA Law by July 22 Deadline (NYSE:OGN) - TradingView
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon LawsuitOGN - WV News
ORGANON BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co.OGN - GlobeNewswire
Investor Alert: Deadline Approaching to Join Organon & Co. (OGN) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Rosen Law Firm Urges Organon & Co. (NYSE: OGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire
OGN Investors Have the Opportunity to Lead the Organon Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
OGN Investors Have the Opportunity to Lead the Organon Securities Fraud Lawsuit with Faruqi ... - Bluefield Daily Telegraph
OGN BREAKING NEWS: Organon & Co. Stock Plummets 27% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NYSE:OGN) - Business Wire
OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm - WV News
ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC ... - Bluefield Daily Telegraph
ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - GlobeNewswire Inc.
OGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
OGN INVESTOR ALERT: Organon & Co. Investors with Substantial Los - GuruFocus
Organon Receives FDA Interchangeability for HADLIMA - TipRanks
Drugmaker Organon Investor Sues After Quarterly Dividend Cut (1) - Bloomberg Law News
Sector Update: Health Care - marketscreener.com
Rosen Law Firm Encourages Organon & Co. Investors to Inquire About Securities Class Action Investigation – OGN - Business Wire
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know - Yahoo
Organon, Samsung Bioepis Say FDA Grants Interchangeability Designation to Hadlima - marketscreener.com
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection - BioSpace
OGN INVESTOR ALERT: Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Organon’s SWOT analysis: healthcare firm’s stock shows growth potential - Investing.com Australia
ORGANON SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co.OGN - Business Wire
Organon’s SWOT analysis: healthcare firm’s stock shows growth potential By Investing.com - Investing.com India
OGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Organon & Co. (NYSE:OGN) Stock Price Down 4.7% – Should You Sell? - Defense World
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon - GlobeNewswire
Lost Money on Organon & Co. (OGN)? Urged to Join Class Action Before July 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
OGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Securities Lawsuit Alert: Organon & Co. (OGN) InvestorsContact Levi & Korsinsky Before July 22, 2025 - ACCESS Newswire
Organon & Co. Investor Notice: Robbins LLP Reminds Investors of the Class Action Against OGN - GlobeNewswire
OGN LAWSUIT ALERT: Levi & Korsinsky Notifies Organon & Co. InvestorsLead Plaintiff Deadline July 22, 2025 - ACCESS Newswire
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organon Co Stock (OGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Falcione Aaron | Chief Human Resources Officer |
May 07 '25 |
Buy |
8.77 |
5,500 |
48,235 |
62,974 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
May 06 '25 |
Buy |
9.21 |
8,045 |
74,054 |
52,489 |
| Karp Daniel | Executive VP, Corp. Dev. |
May 06 '25 |
Buy |
8.24 |
3,500 |
28,828 |
46,669 |
| WALSH MATTHEW M | Chief Financial Officer |
May 05 '25 |
Buy |
8.82 |
11,400 |
100,548 |
144,484 |
| Ali Kevin | Chief Executive Officer |
May 05 '25 |
Buy |
8.80 |
34,000 |
299,370 |
282,731 |
| Falcione Aaron | Chief Human Resources Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,732 |
0 |
59,237 |
| Karp Daniel | Executive VP, Corp. Dev. |
Mar 31 '25 |
Option Exercise |
0.00 |
34,677 |
0 |
44,515 |
| Stahler Rachel A | Chief Information Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,334 |
0 |
78,994 |
| WALSH MATTHEW M | Chief Financial Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
34,870 |
0 |
136,903 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Mar 31 '25 |
Option Exercise |
0.00 |
8,865 |
0 |
20,552 |
0.28%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):